Table 1.
Baseline characteristics of the patients
| Variable | De novo disease Number, no. (%*) | Therapy-related disease Number, no. (%*) |
|---|---|---|
| Number of patients: | 476 (100) | 80 (100) |
| Age in years (median, range) | 45 (17–71) | 47 (21–66) |
| Disease: | ||
| AML | 308 (65) | 21 (26) |
| MDS | 74(16) | 42 (53) |
| RA, RARS, RCMD | 39 (8) | 20 (25) |
| RAEB | 35 (7) | 22 (28) |
| AML from MDS | 94 (20) | 17 (21) |
| AML/mAML stage†: | ||
| 1st CR | 154 (38) | 13 (34) |
| 2nd or higher CR | 102 (25) | 6 (16) |
| Active disease | 146 (36) | 19 (50) |
| Graft | ||
| Bone marrow | 260 (55) | 38(48) |
| Peripheral blood | 207 (43) | 40 (50) |
| Umbilical cord blood | 9 (2) | 2 (3) |
| Match | ||
| MRD | 262 (55) | 31 (39) |
| MUD | 159 (33) | 40 (50) |
| Mismatched | 55 (12) | 9 (11) |
| Mismatched related | 13 (3) | 2 (3) |
| Mismatched unrelated | 42 (9) | 7 (9) |
| Conditioning | ||
| Myeloablative | 381 (80) | 43 (54) |
| Reduced intensity | 95 (20) | 37 (46) |
| GVHD prophylaxis | ||
| CnI +/− Mtx or steroids | 203 (43) | 32 (40) |
| CnI + Siro +/− Mtx | 114 (24) | 24 (30) |
| TCD | 159 (33) | 24 (30) |
| Gender recipient/donor | ||
| Male/Female | 107 (22) | 17 (21) |
| Female/Male | 110 (23) | 25 (31) |
| Female/Female | 114 (24) | 19 (24) |
| Male/Male | 140 (29) | 18 (23) |
| Recipient CMV seropositive | 208 (44) | 28 (35) |
| Donor CMV seropositive | 160 (34) | 29 (36) |
| Year of transplantation | ||
| 1983–1989 | 22 (5) | 3 (4) |
| 1990–1999 | 155 (33) | 24 (30) |
| 2000–2005 | 299 (63) | 53 (66) |
RA indicates refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess blasts; CR, complete remission; MRD, matched related donor; MUD, matched unrelated donor; GVHD, graft-versus-host disease; CnI, calcineurin inhibitor (cyclosporine or tacrolimus); Mtx, methotrexate; Siro, sirolimus; TCD, T-cell depletion; and CMV, cytomegalovirus
*
Percentages may not add to 100 because of rounding
†
Percentage for this category refers to the percent of AML/mAML patients, not to the percent of total patients